23andMe to Cut Workforce by 40%, Discontinues Therapeutics Pipeline

@TheWallStreetJournal partage un lien

2024-11-12 01:07:34 ·

www.wsj.com

The clinical trials 23andMe intends to wind-down include its two main therapeutic programs. The restructuring is expected to result in expenses of up to $12 million, and savings of more than $35 million per year, 23andMe said.

0 Commentaires ·0 Parts ·134 Vue

Connectez-vous pour aimer, partager et commenter!

Mise à niveau vers Pro

Choisissez le forfait qui vous convient

Mise à niveau